000109467 001__ 109467
000109467 005__ 20230519145512.0
000109467 0247_ $$2doi$$a10.3390/jcm10163494
000109467 0248_ $$2sideral$$a125525
000109467 037__ $$aART-2021-125525
000109467 041__ $$aeng
000109467 100__ $$aMarco-Benedí, Victoria$$uUniversidad de Zaragoza
000109467 245__ $$aCataract Surgery in Elderly Subjects with Heterozygous Familial Hypercholesterolemia in Prolonged Treatment with Statins
000109467 260__ $$c2021
000109467 5060_ $$aAccess copy available to the general public$$fUnrestricted
000109467 5203_ $$aBackground: Cataracts are the main cause of blindness and represent one fifth of visual problems worldwide. It is still unknown whether prolonged statin treatment favors the development of cataracts. We aimed to ascertain the prevalence of cataract surgery in elderly subjects with genetically diagnosed heterozygous familial hypercholesterolemia (HeFH) receiving statin treatment for ≥5 years, and compare this with controls. Methods: This is an observational, multicenter, case–control study from five lipid clinics in Spain. We collected data with the following inclusion criteria: age ≥65 years, LDL cholesterol levels ≥220 mg/dL without lipid-lowering drugs, a pathogenic mutation in a candidate gene for HeFH (LDLR, APOB, or PCSK9) and statin treatment for ≥5 years. Controls were selected from relatives of HeFH patients without hypercholesterolemia. Linear and logistic regressions based on generalized linear models and generalized estimating equations (GEE) were used. Cataract surgery was used as a proxy for cataract development. Results: We analyzed 205 subjects, 112 HeFH, and 93 controls, with a mean age of 71.8 (6.5) and 70.0 (7.3) years, respectively. HeFH subjects presented no difference in clinical characteristics, including smoking, hypertension, and type 2 diabetes mellitus, compared with controls. The mean duration of lipid-lowering treatment in HeFH was 22.5 (8.7) years. Cataract surgery prevalence was not significantly different between cases and controls. The presence of cataracts was associated neither with LDLc nor with the length of the statin therapy. Conclusion: In the present study, HeFH was not a risk factor for cataract surgery and prolonged statin treatment did not favor it either. These findings suggest that statin treatment is not related with cataracts.
000109467 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-MINECO/PI19-00694
000109467 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000109467 590__ $$a4.964$$b2021
000109467 592__ $$a1.04$$b2021
000109467 594__ $$a4.4$$b2021
000109467 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000109467 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000109467 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000109467 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, Martín$$uUniversidad de Zaragoza
000109467 700__ $$aSánchez-Hernández, Rosa M.
000109467 700__ $$aOrtega-Martínez de Victoria, Emilio
000109467 700__ $$aPedro-Botet, Juan
000109467 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, Jose$$uUniversidad de Zaragoza
000109467 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, Fernando$$uUniversidad de Zaragoza
000109467 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000109467 773__ $$g10, 16 (2021), 3494 [5 pp.]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000109467 8564_ $$s225463$$uhttps://zaguan.unizar.es/record/109467/files/texto_completo.pdf$$yVersión publicada
000109467 8564_ $$s2685578$$uhttps://zaguan.unizar.es/record/109467/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000109467 909CO $$ooai:zaguan.unizar.es:109467$$particulos$$pdriver
000109467 951__ $$a2023-05-18-15:12:10
000109467 980__ $$aARTICLE